Extracellular control of cell size.

Both cell growth (cell mass increase) and progression through the cell division cycle are required for sustained cell proliferation. Proliferating cells in culture tend to double in mass before each division, but it is not known how growth and division rates are co-ordinated to ensure that cell size is maintained. The prevailing view is that coordination is achieved because cell growth is rate-limiting for cell-cycle progression. Here, we challenge this view. We have investigated the relationship between cell growth and cell-cycle progression in purified rat Schwann cells, using two extracellular signal proteins that are known to influence these cells. We find that glial growth factor (GGF) can stimulate cell-cycle progression without promoting cell growth. We have used this restricted action of GGF to show that, for cultured Schwann cells, cell growth rate alone does not determine the rate of cell-cycle progression and that cell size at division is variable and depends on the concentrations of extracellular signal proteins that stimulate cell-cycle progression, cell growth, or both.

Evidence that axon-derived neuregulin promotes oligodendrocyte survival in the developing rat optic nerve.

It was previously shown that newly formed oligodendrocytes depend on axons for their survival, but the nature of the axon-derived survival signal(s) remained unknown. We show here that neuregulin (NRG) supports the survival of purified oligodendrocytes and aged oligodendrocyte precursor cells (OPCs) but not of young OPCs. We demonstrate that axons promote the survival of purified oligodendrocytes and that this effect is inhibited if NRG is neutralized. In the developing rat optic nerve, we provide evidence that delivery of NRG decreases both normal oligodendrocyte death and the extra oligodendrocyte death induced by nerve transection, whereas neutralization of endogenous NRG increases the normal death. These results suggest that NRG is an axon-associated survival signal for developing oligodendrocytes.

Control of Schwann cell survival and proliferation: autocrine factors and neuregulins.

Postnatal rat Schwann cells secrete factors that prevent the programmed cell death (PCD) of low-density Schwann cells in serum-free culture. These autocrine survival signal(s) do not promote Schwann cell proliferation. Moreover, while NRG and bFGF, which promote proliferation, both rescue a subpopulation of neonatal Schwann cells from PCD, they do not rescue freshly isolated Schwann cells from older animals; other known protein factors tested also do not mimic the autocrine signal. These results suggest that Schwann cells switch their survival dependency around the time of birth from axonal signals such as NRG to autocrine signals. Such an arrangement would be advantageous for the regeneration of peripheral axons following injury. We also compared NRG-induced Schwann cell proliferation using autocrine signals or serum to promote survival. The autocrine signals increase the rate of NRG-stimulated proliferation of low-density Schwann cells in serum-free medium, whereas serum inhibits proliferation by inhibiting both the production of survival signals and the expression of erbB2 and erbB3 receptors; these inhibitions are all reversed by forskolin. In contrast, forskolin has no effect on proliferation when the cells are exposed to high levels of autocrine factors.

Cultured Schwann cells constitutively express the myelin protein P0.

It is widely thought that mammalian Schwann cells do not express Po, the major glycoprotein in peripheral myelin, unless they are induced to do so by axonal signals that can be mimicked by agents that trigger cAMP signaling pathways. In contrast, we find that cultured Schwann cells make large amounts of Po without the addition of any axonal-like signal, provided they have not been exposed to serum during the culture process. We also report that glial growth factor/neuregulin inhibits this constitutive Po expression. Myelin basic protein is regulated in a similar way. We suggest that expression of Po by Schwann cells before the onset of myelination may be prevented by inhibitory signals within the nerve, rather than by the absence of a positive signal from axons.

Programmed cell death by default in embryonic cells, fibroblasts, and cancer cells.

We recently proposed that most mammalian cells constitutively express all of the proteins required to undergo programmed cell death (PCD) and undergo PCD unless continuously signaled by other cells not to. Although some cells have been shown to work this way, the vast majority of cell types remain to be tested. Here we tested purified fibroblasts isolated from developing or adult rat sciatic nerve, a mixture of cell types isolated from normal or p53-null mouse embryos, an immortalized rat fibroblast cell line, and a number of cancer cell lines. We found the following: 1) All of these cells undergo PCD when cultured at low cell density in the absence of serum and exogenous signaling molecules but can be rescued by serum or specific growth factors, suggesting that they need extracellular signals to avoid PCD. (2) The mixed cell types dissociated from normal mouse embryos can only support one another's survival in culture if they are in aggregates, suggesting that cell survival in embryos may depend on short-range signals. (3) Some cancer cells secrete factors that support their own survival. (4) The survival requirements of a human leukemia cell line change when the cells differentiate. (5) All of the cells studied can undergo PCD in the presence of cycloheximide, suggesting that they constitutively express all of the protein components required to execute the death program.

Calcitonin gene-related peptide promotes Schwann cell proliferation.

Schwann cells in culture divide in response to defined mitogens such as PDGF and glial growth factor (GGF), but proliferation is greatly enhanced if agents such as forskolin, which increases Schwann cell intracellular cAMP, are added at the same time as PDGF or GGF (Davis, J. B., and P. Stroobant. 1990. J. Cell Biol. 110:1353-1360). The effect of forskolin is probably due to an increase in numbers of PDGF receptors (Weinmaster, G., and G. Lemke. 1990. EMBO (Eur. Mol. Biol. Organ.) J. 9:915-920. Neuropeptides and beta-adrenergic agonists have been reported to have no effect on potentiating the mitogenic response of either PDGF or GGF. We show that the neuropeptide calcitonin gene-related peptide (CGRP) increases Schwann cell cAMP levels, but the cells rapidly desensitize. We therefore stimulated the cells in pulsatile fashion to partly overcome the effects of desensitization and show that CGRP can synergize with PDGF to stimulate Schwann cell proliferation, and that CGRP is as effective as forskolin in the pulsatile regime. CGRP is a good substrate for the neutral endopeptidase 24.11. Schwann cells in vivo have this protease on their surface, so the action of CGRP could be terminated by this enzyme and desensitization prevented. We therefore suggest that CGRP may play an important role in stimulating Schwann cell proliferation by regulating the response of mitogenic factors such as PDGF.

Onset of CGRP expression and its restriction to a subset of spinal motor neuron pools in the chick embryo is not affected by treatment with curare.

Calcitonin gene-related peptide (CGRP) is expressed in and defines a subset of motor neuron pools in the lumbar spinal cord of the chick embryo. The onset of CGRP expression in individual pools coincides with both the period of the initial innervation of the leg and the beginning of naturally occurring cell death in the lumbar motor column. Administration of neuromuscular blocking agents at this time results in a striking reduction of normal motor neuron loss. It has been reported that such treatment also results in the abolition of CGRP expression at later stages of development. In this study, we have examined the effect of curare treatment on CGRP expression in motor neurons earlier in their development. We find that, in contrast to the effects reported at later stages, inhibition of neuromuscular activity does not affect either the onset of CGRP expression or its restriction to a subset of motor neuron pools. This demonstrates that the control of the onset of CGRP expression is unlikely to be linked to processes which are regulated by neuromuscular transmission including naturally-occurring cell death.

Evidence that CGRP and cAMP increase transcription of AChR alpha-subunit gene, but not of other subunit genes.

Calcitonin gene-related peptide (CGRP) is present in embryonic chick motoneurons and their terminals during myogenesis. We have studied the effect of CGRP on the expression of mRNA encoding the four subunits (alpha, beta, gamma, delta) of ACh receptors in cultured myotubes derived from embryonic chicks. Northern blot analysis showed that treatment with 10(-7) M CGRP caused an increase in ACh receptor alpha-subunit mRNA expression but did not affect the expression of beta-, gamma-, or delta-subunit mRNAs. In addition, CGRP treatment caused an increase in the expression of unspliced alpha-subunit RNA, suggesting that CGRP increases transcription of the alpha-subunit gene. The effect of CGRP on alpha-subunit gene transcription was mimicked by forskolin, and both CGRP and forskolin increased the levels of intracellular cAMP. We infer that the effect of CGRP on alpha-subunit gene transcription is likely to be mediated by the CGRP-induced rise in intracellular cAMP.

Chick myotubes in culture express high-affinity receptors for calcitonin gene-related peptide.

Calcitonin gene-related peptide (CGRP) is a 37-amino acid neuropeptide that is expressed by many neurons of the vertebrate nervous system, including motoneurons of many species. It has been detected immunohistochemically in both cell bodies and motor terminals of motoneurons, suggesting that it may play a role at the neuromuscular junction. In support of this idea, CGRP has been shown to produce a variety of effects on cultured myotubes and muscle explants, including elevation of cAMP levels, increase in cell-surface acetylcholine receptor (AChR) numbers, increase in AChR alpha-subunit mRNA transcript levels, alterations in contractile responses, alterations in the physiological properties of AChRs, and inhibition of insulin-induced changes in glycogen metabolism. CGRP binding sites have been detected in many tissues, but have not yet been demonstrated directly on muscle cells. Here we report that chick myotubes in culture express high-affinity binding sites for CGRP (Kd approximately 2-4 x 10(-10) M). In view of the known biological effects of CGRP on myotubes, we believe that these binding sites represent CGRP receptors. They are uniformly distributed over the surface of myotubes, and we have found no evidence of clustering in culture, in contrast to AChRs. We have found no evidence for more than one class of receptors.

Calcitonin gene-related peptide regulates muscle acetylcholine receptor synthesis.

Innervation of muscle by motoneurones induces the development of a characteristic, high density cluster of acetylcholine receptors (AChRs) at the neuromuscular junction. Studies in vitro show that the accumulation of AChRs at nerve-muscle contacts results from both increased insertion of new AChRs into the muscle plasma membrane beneath nerve terminals and redistribution of preexisting AChRs; these two modes of AChR accumulation may be separately controlled since factors have been identified that influence AChR redistribution but not synthesis. Although many aspects of muscle development are regulated by nerve-dependent muscle activity, junctional AChR clusters still develop when neuromuscular transmission is blocked by either curare or alpha-bungarotoxin, suggesting that their formation is mediated by nerve-derived trophic factors other than activity. A molecule immunologically related to calcitonin gene-related peptide (CGRP-I) has been found in motoneurones in a variety of mammals including man. Here we provide indirect evidence that CGRP-I may be a motoneurone-derived trophic factor that increases AChR synthesis at vertebrate neuromuscular junctions.

Distribution and ontogeny of SP, CGRP, SOM, and VIP in chick sensory and sympathetic ganglia.

The distribution and ontogeny of four neuropeptides in developing chick lumbosacral sensory and sympathetic ganglia were studied using immunohistochemical techniques. Antibodies to two of these peptides, substance P (SP) and calcitonin gene-related peptide (CGRP), stained small neurons in the medial part of the dorsal root ganglia from embryonic Day 5 and Day 10, respectively, whereas neurons in the lateral part of the ganglia were negative; this distribution persisted throughout development. Both sets of neurons apparently send fibers to the dorsal horn of the spinal cord: SP to laminae I and II, and CGRP to lamina I, suggesting that the SP- and CGRP-positive sensory neurons are nociceptive or thermoreceptive. This correlation between the presence of SP or CGRP in a neuron and a particular functional modality thus provides evidence for a functional distinction between the mediodorsal and ventrolateral zones that are apparent during the development of chick dorsal root ganglia. Moreover, this study suggests that the type of neuron that develops within the dorsal root ganglion correlates with its position within the ganglion. In contrast to SP and CGRP, somatostatin (SOM) and vasoactive intestinal polypeptide (VIP) immunoreactivities were not seen in the lumbosacral sensory ganglia at any stage during development. However, both were present in sympathetic ganglia: SOM from embryonic Day 4.5 and VIP from embryonic Day 10. VIP immunoreactivity persisted throughout development in a large number of sympathetic neurons, but the number of cells with SOM immunoreactivity decreased from embryonic Day 10 onward. SOM therefore appears to be present only transiently in most chick lumbosacral sympathetic cells.

Somatostatin alters beta-adrenergic receptor-effector coupling in cultured rat astrocytes.

The neuropeptide somatostatin potentiates beta-adrenergic receptor-mediated cAMP formation in astrocytes derived from neonatal rat cortex but does not affect cAMP levels by itself. beta-Adrenergic receptors in these cells can be specifically labeled with the high affinity antagonist [125I] cyanopindolol ([125I]CYP). In addition, astrocytes display both high and low affinity binding sites for the agonist isoproterenol, which are thought to represent receptors which are coupled or uncoupled, respectively, to the guanine nucleotide regulatory protein. We find that somatostatin does not modify beta-receptor density, nor receptor affinity for either the antagonist ([125I]CYP) or for the agonist isoproterenol. In the presence of the guanine nucleotide analogue, Gpp(NH)p, only low affinity (uncoupled) displacement of [125I]CYP binding by isoproterenol is observed. However, somatostatin (1 microM), when added to the cells together with Gpp(NH)p, prevents the nucleotide-induced loss of the high affinity (coupled) component of agonist displacement. This result suggests that somatostatin increases noradrenaline-induced cAMP production by enhancing coupling between the beta-receptor and the stimulatory guanine nucleotide regulatory protein.

Schwann cells induce morphological transformation of sensory neurones in vitro.

Cell-cell interactions are thought to play a crucial part in determining the developmental fate of vertebrate cells and regulating their subsequent differentiation. In the peripheral nervous system, for example, signals from neuronal axons determine whether or not some Schwann cells wrap their plasma membrane concentricially around the axon to form a myelin sheath. Moreover, there is some evidence that the interactions between Schwann cells and neurones are not all one way: for example, Schwann cells are thought to provide signals for neuronal sprouting and regeneration. However, there are no clear examples in which Schwann cells have been shown to influence the normal development of neurones. Here I have used purified populations of embryonic sensory neurones and Schwann cells to demonstrate that Schwann cells have a dramatic influence on the development of these neurones. In the presence of Schwann cells, but not other cell types, the sensory neurones undergo a morphological transformation from an immature bipolar form to a mature pseudo-unipolar form. This provides a striking example of the importance of glial cells for neuronal development.

Neuropeptides modulate the beta-adrenergic response of purified astrocytes in vitro.

Neuropeptides may have functions in the central nervous system (CNS) other than altering neuronal excitability. For example, they may act as regulators of brain metabolism by affecting glycogenolysis. Since it has been suggested that glial cells might provide metabolic support for neuronal activity, they may well be one of the targets for neuropeptide regulation of metabolism. Consistent with this view are reports that peptide-containing nerve terminals have been seen apposed to astrocytes, but it is also quite possible that peptides could act at sites lacking morphological specialization. Primary cultures containing CNS glial cells have been shown to respond to beta-adrenergic agonists with an increase in cyclic AMP and, as a result, with an increase in glycogenolysis and have also been shown to respond to a variety of peptides with changes in cyclic AMP. In the study reported here, we have examined the effects of several peptides on relatively pure cultures of rat astrocytes. We demonstrate that the increase in intracellular cyclic AMP induced by noradrenaline is markedly enhanced by somatostatin and substance P and is inhibited by enkephalin, even though these peptides on their own have little or no effect on the basal levels of cyclic AMP. Vasoactive intestinal peptide (VIP) on the other hand increases cyclic AMP in the absence of noradrenaline. These results suggest that neuropeptides influence glial cells as well as neurones in the CNS and, in the case of somatostatin and substance P, provide further examples of neuropeptides modulating the response to another chemical signal without having a detectable action on their own.

A subpopulation of rat dorsal root ganglion neurones is catecholaminergic.

The neurotransmitters used by the sensory neurones of the dorsal root ganglia (DRG) are unknown. A proportion of these cells contain physiologically active peptides; for example, subpopulations of small-diameter neurones contain substance P or somatostatin. Although these peptides probably have some influence on synaptic transmission in the dorsal horn of the spinal cord, their status as neurotransmitters is uncertain and it is possible that they coexist with conventional neurotransmitters. In addition, the neurones containing identified peptides account for only a fraction of the DRG sensory neurones. There is evidence that the DRG contain catecholamines within fibres thought to be autonomic, but these substances have not been found within the sensory cell bodies themselves. Moreover, the apparently inappropriate, inhibitory physiological effect of catecholamines in the dorsal horn has argued against their being primary sensory neurotransmitter molecules. We have used here antisera against tyrosine hydroxylase (TH; EC 1.14.16.2) and dopamine-beta-hydroxylase (DBH; EC 1.14.17.1), two enzymes specific to catecholaminergic cells, to show that a subpopulation of rat DRG neurones is catecholaminergic and that the neurotransmitter they make is probably dopamine. We believe this to be the first report of catecholaminergic sensory neurones.

Effect of non-neuronal cells on peptide content of cultured sensory neurones.

The peptide substances P (SP) and somatostatin (SOM) are present in small-diameter neurones of dorsal root ganglia (DRG) and in small-diameter fibres that project to the spinal cord dorsal horn. It is not known whether SP or SOM coexist with other transmitter molecules but, since both peptides can be released from sensory neurones and both can alter neuronal firing rates in the dorsal horn, it seems likely that they are involved in some way in synaptic transmission in the spinal cord. SP has generally excitatory effects in the spinal cord whereas SOM exerts inhibitory effects, and it is not at all clear which subclass of nociceptive afferents contain SP or SOM. Mudge, Leeman & Fischbach (1979) have studied sensory neurones derived from chick DRG grown in dissociated cell culture. When the neurones are grown in the absence of non-neuronal cells, they contain SP but relatively little SOM. The amount of SOM produced by these neurones is greatly increased (c. 50-fold) when the neurones are grown together with ganglionic non-neuronal cells or with medium 'conditioned' by incubation with such cells. The increase in SOM content is not accompanied by an increase in SP content or a detectable change in neuronal survival. The DRG non-neuronal cells consist of two major cell types--glial cells and fibroblasts. Indirect evidence suggests that glial cells rather then fibroblasts are responsible for the increased production of SOM by the neurones. Raff and his colleagues (Brockes, Fields & Raff, 1979) have used immunological techniques to obtain purified cultures of these two cell types. Work currently in progress is aimed at extending the above observations to the rat and firmly establishing whether glial cells can indeed influence SOM production in sensory neurones.